| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Ziccum AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.52 |
| 52 Week High | SEK 0.84 |
| 52 Week Low | SEK 0.42 |
| Beta | 1.29 |
| 11 Month Change | 7.60% |
| 3 Month Change | -3.68% |
| 1 Year Change | 11.97% |
| 33 Year Change | -70.73% |
| 5 Year Change | n/a |
| Change since IPO | -79.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7IZ | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0.4% | -4.8% | 0.8% |
| 1Y | 12.0% | -19.4% | 2.0% |
Return vs Industry: 7IZ exceeded the German Pharmaceuticals industry which returned -19.4% over the past year.
Return vs Market: 7IZ exceeded the German Market which returned 2% over the past year.
Price Volatility
| 7IZ volatility | |
|---|---|
| 7IZ Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 7IZ has not had significant price volatility in the past 3 months.
Volatility Over Time: 7IZ's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 9 | Ann Gidner | ziccum.com |
Ziccum AB (publ) develops dry powder preparations of biological pharmaceuticals. It develops and commercializes LaminarPace, a spray drying technology that dries liquid biopharmaceuticals, such as vaccines or protein therapeutics into a particle engineered powder product. The company was incorporated in 2017 and is headquartered in Lund, Sweden.
Ziccum AB (publ) Fundamentals Summary
| 7IZ fundamental statistics | |
|---|---|
| Market cap | €8.46m |
| Earnings (TTM) | -€1.81m |
| Revenue (TTM) | €786.48k |
10.8x
P/S Ratio-4.7x
P/E RatioIs 7IZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7IZ income statement (TTM) | |
|---|---|
| Revenue | SEK 8.93m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 8.93m |
| Other Expenses | SEK 29.43m |
| Earnings | -SEK 20.50m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 30, 2024
| Earnings per share (EPS) | -1.33 |
| Gross Margin | 100.00% |
| Net Profit Margin | -229.59% |
| Debt/Equity Ratio | 5.4% |
How did 7IZ perform over the long term?
See historical performance and comparison